drugset / Trial / NCT02805166

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

NCT02805166

Phase 4 Completed 420 enrolled CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lung cancer,head and neck cancer,colorectal cancer,and ovarian cancer receiving multi-cycle chemotherapy.

Timeline

Start
2013-04
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 100 ug/kg Subcutaneous

Indications